Adults 25 to 55, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Quality of Life : EORTC QLQ-C30 ScoresPrimary· At baseline and 5 months
Standardised QLQ-C30 scoring according to EORTC scoring manual (Fayers et al. EORTC QLQ-C30 scoring manual. 2001).
15 dimensions are presented below. Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health.
Global health status/ quality of life - Baseline
Group
Value
95% CI
Psychological and Social Consultation
61.0
54.3 – 67.7
Global health status/ quality of life - 5 months
Group
Value
95% CI
Psychological and Social Consultation
70.8
66.1 – 75.5
Physical functioning - Baseline
Group
Value
95% CI
Psychological and Social Consultation
82.9
78.8 – 86.9
Physical functioning - 5 months
Group
Value
95% CI
Psychological and Social Consultation
83.2
78.7 – 87.6
Role functioning - Baseline
Group
Value
95% CI
Psychological and Social Consultation
72.6
63.6 – 81.6
Role functioning - 5 months
Group
Value
95% CI
Psychological and Social Consultation
78.6
70.2 – 87.0
Emotional functioning - Baseline
Group
Value
95% CI
Psychological and Social Consultation
61.0
51.3 – 70.7
Emotional functioning - 5 months
Group
Value
95% CI
Psychological and Social Consultation
67.0
57.9 – 76.0
Cognitive Complaints : FACT Cog Scale ScoresPrimary· At baseline and 5 months
Cognitive complaints were evaluated by using the french Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scale version 3
Assessed using median total score (range 0-132) and median scores of these 4 dimensions :
* Perceived Cognitive Impairment (range 0-72)
* Impact on quality of life (range 0-16)
* Comments from others (range 0-16)
* Perceived Cognitive Skills (range 0-28) Higher scores indicate better cognitive functioning.
Perceived Cognitive Impairment - Baseline
Group
Value
95% CI
Psychological and Social Consultation
39
8 – 69
Perceived Cognitive Impairment - 5 months
Group
Value
95% CI
Psychological and Social Consultation
50.5
7 – 72
Impact on quality of life - Baseline
Group
Value
95% CI
Psychological and Social Consultation
8
0 – 16
Impact on quality of life - 5 months
Group
Value
95% CI
Psychological and Social Consultation
14.0
0 – 16
Comments from others - Baseline
Group
Value
95% CI
Psychological and Social Consultation
15
5 – 16
Comments from others - 5 months
Group
Value
95% CI
Psychological and Social Consultation
16
3 – 16
Perceived Cognitive Skills - Baseline
Group
Value
95% CI
Psychological and Social Consultation
13
3 – 25
Perceived Cognitive Skills - 5 months
Group
Value
95% CI
Psychological and Social Consultation
17.5
0 – 27
Professional Recovery Scale ScoresPrimary· At baseline and 5 months
Professional recovery was evaluated by using the Scale of motivation to Professional recovery.
This scale was constructed for the needs of this exploratory research and has for vocation a later validation.
It includes 62 questions and was assessed using median scores of these 7 dimensions :
* Work and administrative process (0-100)
* Positioning in relation to the job-post-mission (0-100)
* Emotion and work (0-100)
* Labour relations (0-100)
* Work and physical/intellectual conditions (0-100)
* Privacy and work (0-100)
* Return to work (0-20) Higher scores represent better outcomes
Work and administrative process - Baseline
Group
Value
95% CI
Psychological and Social Consultation
58
44 – 73
Work and administrative process - 5 months
Group
Value
95% CI
Psychological and Social Consultation
61
34 – 80
Positioning in relation to the job-post-mission - Baseline
Group
Value
95% CI
Psychological and Social Consultation
40.5
13 – 75
Positioning in relation to the job-post-mission - 5 months
Group
Value
95% CI
Psychological and Social Consultation
50
10 – 73
Emotion and work - Baseline
Group
Value
95% CI
Psychological and Social Consultation
58.5
28 – 88
Emotion and work - 5 months
Group
Value
95% CI
Psychological and Social Consultation
60
33 – 91
Labour relations - Baseline
Group
Value
95% CI
Psychological and Social Consultation
55
11 – 90
Labour relations - 5 months
Group
Value
95% CI
Psychological and Social Consultation
59
28 – 90
Tiredness : Piper MFI-20 Scale ScoresSecondary· At baseline and 5 months
Tiredness was evaluated by using the Piper Multidimensional Fatigue Inventory (MFI-20) revised scale
Assessed using median total score (range 0-10) and median scores of these 4 tiredness dimensions :
* Behavioural
* Emotional
* Sensory
* Cognitive-mood Each dimension has range 0-10 with following interpretation: higher scores indicate greater severity of fatigue
Emotional dimension - Baseline
Group
Value
95% CI
Psychological and Social Consultation
5.4
1.6 – 9.8
Behavioural dimension - 5 months
Group
Value
95% CI
Psychological and Social Consultation
4.7
0.5 – 9.2
Behavioural dimension - Baseline
Group
Value
95% CI
Psychological and Social Consultation
5.3
0.0 – 9.7
Emotional dimension - 5 months
Group
Value
95% CI
Psychological and Social Consultation
5.7
2.0 – 9.8
Sensory dimension - Baseline
Group
Value
95% CI
Psychological and Social Consultation
4.2
0.6 – 7.6
Sensory dimension - 5 months
Group
Value
95% CI
Psychological and Social Consultation
4.0
0.8 – 7.2
Cognitive-mood dimension - Baseline
Group
Value
95% CI
Psychological and Social Consultation
4.8
0.5 – 7.7
Cognitive-mood dimension - 5 months
Group
Value
95% CI
Psychological and Social Consultation
3.9
0.3 – 6.3
Anxio-depressive Troubles : HAD Scale ScoresSecondary· At baseline and 5 months
Anxio-depressive troubles were evaluated by using the Hospital Anxiety and Depression (HAD) scale.
Assessed using median scores of these 2 dimensions :
* Anxiety
* Depression Each dimension has range 0-21 with following interpretation: higher scores represent worse outcomes (0-7 normal; 8-10 mild; 11-14 moderate; 15-21 severe)
Anxiety score - Baseline
Group
Value
95% CI
Psychological and Social Consultation
10.0
1 – 19
Anxiety score - 5 months
Group
Value
95% CI
Psychological and Social Consultation
8
2 – 18
Depression score - Baseline
Group
Value
95% CI
Psychological and Social Consultation
7.0
4 – 18
Depression score - 5 months
Group
Value
95% CI
Psychological and Social Consultation
6.5
3 – 12
Sponsor's own description
This patient support system is designed to help patients regain their professional activity after their treatment. It's a 3-Axis neuropsycho-social synergy on 3 axes:
* A weekly pluridisciplinary consultation in tandem (Social worker + Psychologist / Neuropsychologist)
* Monthly information meetings and workshops (TIC'Onco reunions: collective information times and Cogit'Onco workshops: cognitive workshops
* An information booklet "Prepare the work return" The aim of this research is to evaluate efficiency in term of quality of life improvement linked to work status, utility, feasibility and patients' satisfaction.
The aim of this research is to evaluate efficiency in term of quality of life improvement linked to work status, utility, feasibility and patients' satisfaction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors
· NA
· recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy
· NA
· recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients.
· NA
· recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations
· NA
· recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety
· NA
· recruiting
Other Institut Bergonié trials
Trials by the same sponsor.
NCT06084689 — Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
· Phase 2
· withdrawn
NCT06700057 — Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
· recruiting
NCT05690828 — Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer.
· NA
· active not recruiting
NCT05415527 — Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Mana
· NA
· active not recruiting
NCT04912687 — Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients
· NA
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Bergonié
Last refreshed: 4 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03302767.